Search

Search Constraints

You searched for: Author/Creator Cluzeau, Thomas

Search Results

1. A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations. (19th April 2022)

3. Azacitidine for the treatment of relapsed and refractory AML in older patients. Issue 2 (February 2015)

4. Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients. (11th May 2020)

5. Azacitidine in untreated acute myeloid leukemia: A report on 149 patients. Issue 4 (6th February 2014)

6. Clonal selection in therapy‐related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment. (9th March 2020)

7. Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast‐phase myeloproliferative neoplasms. (10th June 2015)

10. Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real‐life study. (20th June 2021)